RxDoctor Payments Data

Seung Lee, MD

Otolaryngology · Honolulu, HINPI 1750313011

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 88 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $824 and has fallen 58.6% since, to $341 in 2025.

$2,842in general payments, 2019–2025

Across 88 payments — averaging $32.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acclarent, Inc$647
  • Regeneron Healthcare Solutions, Inc.$596
  • Stryker$394
  • GSK$358
  • Intersect ENT, Inc.$239
  • Sanofi$176
  • plus $431 from 5 others
$299,635in research payments, 2019–2025

Across 12 payments — averaging $24,970 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$300K

What the payments were for

  • Food & beverage$2,842100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,842 in reported general payments places this provider in the 75th percentile of 33 otolaryngology providers in Hawaii.

See all otolaryngology providers in Hawaii

Medicare billing

Part B allowed, 2024
$578,969
Medicare patients
834
Services billed
3,982

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fluticasone Propionate327$8,508
Azelastine Hcl113$7,370
Mometasone Furoate14$2,937
Azelastine-FluticasoneAzelastine/Fluticasone13$2,043
Ofloxacin29$1,621
Famotidine55$886
Montelukast Sodium14$546
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav22$265
Omeprazole16$215
Gabapentin11$171
Amoxicillin11$34
Prednisone19$20

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →